

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Rischin, D;Khushalani, N;Schmults, C;Guminski, A;Chang, AL;Lewis, K;Lim, A;Hernandez-Aya, L;Hughes, B;Schadendorf, D;Hauschild, A;Stankevich, E;Booth, J;Yoo, S-Y;Chen, Z;Okoye, E;Lowy, I;Fury, M;Migden, M

Title:

Phase 2 Study of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Longer Follow-Up

Date:

2020-10-27

Citation:

Rischin, D., Khushalani, N., Schmults, C., Guminski, A., Chang, A. L., Lewis, K., Lim, A., Hernandez-Aya, L., Hughes, B., Schadendorf, D., Hauschild, A., Stankevich, E., Booth, J., Yoo, S. -Y., Chen, Z., Okoye, E., Lowy, I., Fury, M. & Migden, M. Phase 2 Study of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Longer Follow-Up. [Abstract]. SKIN The Journal of Cutaneous Medicine, 4 (6), pp.s124-s124. <https://doi.org/10.25251/skin.4.suppl.124>.

Persistent Link:

<https://hdl.handle.net/11343/288778>

License:

CC BY

Phase 2 Study of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Longer Follow-Up

Danny Rischin,¹ Nikhil I. Khushalani,² Chrysalyne D. Schmults,³ Alexander Guminski,⁴ Anne Lynn S. Chang,⁵ Karl D. Lewis,⁶ Annette M. Lim,¹ Leonel Hernandez-Aya,⁷ Brett G.M. Hughes,⁸ Dirk Schadendorf,⁹ Axel Hauschild,¹⁰ Elizabeth Stankevich,¹¹ Jocelyn Booth,¹¹ Suk-Young Yoo,¹¹ Zhen Chen,¹² Emmanuel Okoye,¹³ Israel Lowy,¹² Matthew G. Fury,¹² Michael R. Migden¹⁴

¹Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; ²Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA; ³Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA;

⁴Department of Medical Oncology, Royal North Shore Hospital, St Leonards, Australia; ⁵Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, USA; ⁶University of Colorado Denver, School of Medicine, Aurora, CO, USA;

⁷Division of Medical Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA; ⁸Royal Brisbane & Women's Hospital and University of Queensland, Brisbane, Australia; ⁹University Hospital Essen, Essen and German Cancer Consortium, Essen, Germany;

¹⁰Schleswig-Holstein University Hospital, Kiel, Germany; ¹¹Regeneron Pharmaceuticals, Inc., Basking Ridge, NJ, USA; ¹²Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; ¹³Regeneron Pharmaceuticals, Inc., London, UK;

¹⁴Departments of Dermatology and Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA

Synopsis

- Cutaneous squamous cell carcinoma (CSCC) is the second most common cancer in the US and its incidence is increasing.¹
- Most cases of CSCC are cured by complete surgical excision.^{2,3} However, a small but substantial number of patients present with either metastatic CSCC (mCSCC) or locally advanced CSCC (laCSCC) not amenable to curative surgery or curative radiotherapy (collectively referred to as “advanced CSCC”), both of which have poor prognoses.^{4–6}
- Historical data shows median overall survival (OS) of approximately 15 months with conventional chemotherapy or epidermal growth factor receptor inhibitors.⁷
- Cemiplimab is a high-affinity, highly potent human immunoglobulin G4 monoclonal antibody to the programmed cell death (PD)-1 receptor.⁸
- Cemiplimab monotherapy achieved clinically meaningful activity in patients with advanced CSCC and has a safety profile consistent with other anti-PD-1 agents.^{9–11}
- Based on initial data (median follow-up of 9.4 months in the pivotal study, NCT02760498), cemiplimab (cemiplimab-rwlc in the US) was approved for the treatment of patients with advanced CSCC.


Objectives

- The primary objective of the Phase 2 study was to evaluate the objective response rate (ORR) by independent central review (ICR) per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) (for scans)¹² and modified World Health Organization (WHO) criteria (for photos).
- Key secondary objectives included ORR per investigator review (INV), duration of response (DOR) by ICR and INV, progression-free survival (PFS) by ICR and INV, OS, complete response rate by ICR, safety and tolerability, and assessment of health-related quality of life. Durable disease control rate, defined as the proportion of patients with response or stable disease for at least 105 days, was also examined.
- Here, we present up to 3-year follow-up (median duration of follow-up for all patients: 15.7 months) from the largest and most mature prospective data set in advanced CSCC.

Methods

- EMPOWER-CSCC-1 is an open-label, non-randomized, multicenter, international Phase 2 study of patients with advanced CSCC.
- Patients received cemiplimab 3 mg/kg every 2 weeks (Q2W) (Group 1; mCSCC; Group 2, laCSCC) or cemiplimab 350 mg every 3 weeks (Q3W) (Group 3, mCSCC) (Figure 1).
- The severity of treatment-emergent adverse events (TEAEs) was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.03).
- The data cut-off was October 11, 2019.

Figure 1. Study design



Results

Patients

- A total of 193 patients were enrolled (Group 1, n=59; Group 2, n=78; Group 3, n=56) (Table 1).

Table 1. Baseline demographics


	Advanced CSCC (n=193)
Median age, years (range)	72.0 (38–96)
Male, n (%)	161 (83.4)
ECOG performance status, n (%)	
0	86 (44.6)
1	107 (55.4)
Primary CSCC site: head and neck, n (%)	131 (67.9)
mCSCC, n (%)	115 (59.6)
laCSCC, n (%)	78 (40.4)
Patients with cemiplimab as first-line therapy, n (%)	128 (66.3)
Patients with prior systemic therapy, n (%) [†]	65 (33.7)
Median duration of exposure to cemiplimab, weeks (range)	51.1 (2.0–109.3)
Median number of doses of cemiplimab administered (range)	18.0 (1–48)

[†]Settings for prior lines of therapy included metastatic disease, adjuvant, chemotherapy with concurrent radiation, or other and the most common types of prior systemic therapy were platinum compounds (n=46/65 [70.8%]) and monoclonal antibodies (n=18/65 [27.7%]).

Clinical activity

- Complete response rates at primary analysis, ~1-year follow-up for Groups 1, 2, and 3, and ~2-year follow-up for Group 1 are shown in Figure 2.
- Among 89 responders, median time to complete response was 11.2 months (interquartile range [IQR], 7.4–14.8).

Figure 2. Complete response rates per ICR



[†]Among 23 laCSCC patients who were included in the pre-specified Group 2 interim analysis, there were no complete responses.


Table 2. Duration of follow-up and tumor response to cemiplimab per ICR

	Group 1 (mCSCC) 3 mg/kg Q2W (n=59)	Group 2 (laCSCC) 3 mg/kg Q2W (n=78)	Group 3 (mCSCC) 350 mg Q3W (n=56)	Total (n=193)
Median duration of follow-up, months (range)	18.5 (1.1–36.1)	15.5 (0.8–35.6)	17.3 (0.6–26.3)	15.7 (0.6–36.1)
ORR, % (95% CI)	50.8 (37.5–64.1)	44.9 (33.6–56.6)	42.9 (29.7–56.8)	46.1 (38.9–53.4)
Complete response, n (%)	12 (20.3)	10 (12.8)	9 (16.1)	31 (16.1)
Partial response, n (%)	18 (30.5)	25 (32.1)	15 (26.8)	58 (30.1)
Stable disease, n (%)	9 (15.3)	27 (34.6)	10 (17.9)	46 (23.8)
Non-complete response/non-progressive disease, n (%)	3 (5.1)	0	2 (3.6)	5 (2.6)
Progressive disease, n (%)	10 (16.9)	10 (12.8)	14 (25.0)	34 (17.6)
Not evaluable, n (%)	7 (11.9)	6 (7.7)	6 (10.7)	19 (9.8)
Disease control rate, % (95% CI)	71.2 (57.9–82.2)	79.5 (68.8–87.8)	64.3 (50.4–76.6)	72.5 (65.7–78.7)
Durable disease control rate, [†] % (95% CI)	61.0 (47.4–73.5)	62.8 (51.1–73.5)	57.1 (43.2–70.3)	60.6 (53.3–67.6)
Median observed time to response, months (IQR) [‡]	1.9 (1.8–2.0)	2.1 (1.9–3.8)	2.1 (2.1–4.2)	2.1 (1.9–3.7)
Median observed time to complete response, months (IQR)	11.1 (7.5–18.4)	10.5 (7.4–12.9)	12.4 (8.2–16.6)	11.2 (7.4–14.8)
Median DOR, months (95% CI) [‡]	NR (20.7–NE)	NR (18.4–NE)	NR (28.8–NE)	NR (28.8–NE)
Kaplan–Meier 12-month estimate of patients with ongoing response, % (95% CI)	89.5 (70.9–96.5)	83.2 (64.1–92.7)	91.7 (70.6–97.8)	87.8 (78.5–93.3)
Kaplan–Meier 24-month estimate of patients with ongoing response, % (95% CI)	68.8 (46.9–83.2)	62.5 (38.4–79.4)	NE (NE, NE)	69.4 (55.6–79.6)

[†]Defined as the proportion of patients without progressive disease for at least 105 days.
[‡]Based on number of patients with confirmed complete or partial response.
ORR per INV was 54.4% (95% CI: 47.1–61.6) for all patients; 50.8% (95% CI: 37.5–64.1) for Group 1, 56.4% (95% CI: 44.7–67.6) for Group 2, and 55.4% (95% CI: 41.5–68.7) for Group 3. ORR per INV was 57.8% (95% CI: 48.8–66.5) among treatment-naïve patients and 47.7% (95% CI: 35.1–60.5) among previously treated patients.
CI, confidence interval; NE, not evaluable; NR, not reached.


- ORR per ICR was 46.1% (95% CI: 38.9–53.4) among all patients; 50.8% (95% CI: 37.5–64.1) for Group 1, 44.9% (95% CI: 33.6–56.6) for Group 2, and 42.9% (95% CI: 29.7–56.8) for Group 3 (Table 2).
- Per ICR, ORR was 48.4% and 41.5% among those who had not received prior anticancer systemic therapy (n=128) and those who had received prior anticancer systemic therapy (n=65), respectively.
- Overall, the observed time to response was 2 months for 41 (46.1%) patients, 2–4 months for 29 (32.6%) patients, 4–6 months for eight (9.0%) patients, and >6 months for 11 (12.4%) patients.
- Median DOR has not been reached (observed DOR range: 1.9–34.3 months). In responding patients, the estimated proportion of patients with ongoing response at 24 months was 69.4% (95% CI: 55.6–79.6) (Figure 3).

Figure 3. Kaplan–Meier curves of DOR per ICR



- Estimated median PFS was 18.4 months (95% CI: 10.3–24.3) for all patients. The Kaplan–Meier estimated progression-free probability at 24 months was 44.2% (95% CI: 36.1–52.1) (Figure 4A).
- Median OS has not been reached. The Kaplan–Meier estimated probability of OS at 24 months was 73.3% (95% CI: 66.1–79.2) (Figure 4B).

Figure 4. Kaplan–Meier curves for A) PFS per ICR and B) OS



Treatment-emergent adverse events

- In total, 192 (99.5%) patients experienced at least one TEAE of any grade regardless of attribution (Table 3).
- Overall, the most common TEAEs of any grade were fatigue (n=67, 34.7%), diarrhea (n=53, 27.5%), and nausea (n=46, 23.8%).
- Grade ≥3 TEAEs regardless of attribution occurred in 94 (48.7%) of patients. The most common Grade ≥3 TEAEs were hypertension (n=9; 4.7%) and anemia and cellulitis (each n=8; 4.1%).
- Grade ≥3 treatment-related adverse events (TRAEs) were reported in 33 (17.1%) patients, with the most common being pneumonitis (n=5, 2.6%), autoimmune hepatitis (n=3; 1.6%), anemia, colitis, and diarrhea (all n=2; 1.0%).
- No new TEAEs resulting in death were reported compared to previous reports.^{9–11}

Table 3. TEAEs regardless of attribution

	Advanced CSCC (n=193)	
n (%)	Any grade	Grade ≥3
Any	192 (99.5)	94 (48.7)
Led to discontinuation	19 (9.8)	14 (7.3)
Most common [†]		
Fatigue	67 (34.7)	5 (2.6)
Diarrhea	53 (27.5)	2 (1.0)
Nausea	46 (23.8)	0
Pruritus	41 (21.2)	0
Rash	32 (16.6)	1 (0.5)
Cough	32 (16.6)	0
Arthralgia	28 (14.5)	1 (0.5)
Constipation	26 (13.5)	1 (0.5)
Vomiting	24 (12.4)	1 (0.5)
Actinic keratosis	23 (11.9)	0
Maculopapular rash	23 (11.9)	1 (0.5)
Anemia	22 (11.4)	8 (4.1)
Hypothyroidism	22 (11.4)	0
Headache	21 (10.9)	0
Upper respiratory tract infection	20 (10.4)	0

[†]TEAEs reported in ≥10% of patients, ordered by frequency of any grade.

Summary and Conclusion

- For patients with advanced CSCC, cemiplimab achieved ORR of 46.1%.
- Patients had deepening responses over time as evidenced by increasing complete response rates.^{9–11} Overall, the complete response rate is now 16.1% and median time to complete response was 11.2 months.
- DOR and OS are longer than what has been previously described with other agents.⁷
- With median DOR not reached after an additional 1 year of follow-up, this analysis indicates an increasing, clinically meaningful DOR with cemiplimab.
- The discontinuation rate, regardless of attribution, was low and most TRAEs were Grades 1–2.

Post hoc analysis of health-related quality of life in the same patient population is presented in the poster titled “Health-Related Quality of Life (HRQL) in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC) Treated with Cemiplimab: Post Hoc Exploratory Analysis of a Phase 2 Clinical Trial”, also available on the 2020 Fall Clinical Dermatology Conference platform.

References

1. Que SKT et al. *J Am Acad Dermatol*. 2018;78:237–247.
2. Cramer LD et al. *Oncologist*. 2010;15:1320–1328.
3. National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology: squamous cell skin cancer version 2.2019. 2019. Available at: https://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf. [Accessed March 20, 2020].
4. Kania PS et al. *J Clin Oncol*. 2014;32:3237–3241.
5. Weinberg AB et al. *Dermatol Surg*. 2007;33:885–889.
6. Schmults CD et al. *JAMA Dermatol*. 2013;149:541–547.
7. Cowey C et al. *Cancer Med*. 2020 [in press].
8. Barua E et al. *Am J Cancer Ther*. 2017;16:861–870.
9. Migden M et al. *Lancet Oncol*. 2020;21:394–405.
10. Migden M et al. *J Clin Oncol*. 2018;36:3534–3541.
11. Rischin D et al. Poster presented at Maui Dermatology Conference, January 29–29, 2020.
12. Eisenhauer EA et al. *Eur J Cancer*. 2009;45:228–247.

Acknowledgments

The authors would like to thank the patients, their families, all other investigators, and all investigational site members involved in this study. The study was funded by Regeneron Pharmaceuticals, Inc. and Sanofi. Medical writing support and copyediting was provided by Kate Cantley, PhD, of Prime Knowledge, UK, funded by Regeneron Pharmaceuticals, Inc. and Sanofi. For any questions or comments, please contact Dr Danny Rischin, Danny.Rischin@pma.org.

Disclosures

Danny Rischin reports institutional research grant and funding from Regeneron Pharmaceuticals, Inc., Roche, Merck Sharp & Dohme, Bristol-Myers Squibb, and GlaxoSmithKline; uncompensated scientific committee and advisory board from Merck Sharp & Dohme, Regeneron Pharmaceuticals, Inc., Sanofi, GlaxoSmithKline, and Bristol-Myers Squibb; travel and accommodation from Merck Sharp & Dohme and GlaxoSmithKline; Nikhil I. Khushalani reports grants from Regeneron Pharmaceuticals, Inc.; grants and advisory board fees from Bristol-Myers Squibb and HUYA Bioscience International; advisory board fees from MSD Serono, Regeneron Pharmaceuticals, Inc., Genentech, AstraZeneca (data safety monitoring committee), Merck, APRIV, Biopharma, Janssen Therapeutics, and Immunocore; grants from Merck, Novartis, GlaxoSmithKline, Celgene, and Amgen; honorarium from Sanofi; and common stock ownership of Bellum Pharmaceuticals, Mazor Robotics, Amaris, and Transnervix; Chrysalyne D. Schmults reports steering committee member for Celis Bioscience; a steering committee member and consultant for Regeneron Pharmaceuticals, Inc.; a consultant for Sanofi; research funding from Celis Bioscience, Regeneron Pharmaceuticals, Inc., Novartis, Genentech, and Merck; and is a chair for the National Comprehensive Cancer Network; Alexander Guminski reports personal fees and non-financial support (advisory board and travel support) from Bristol-Myers Squibb and Sanofi; personal fees (advisory board from Merck KGaA, Eisai, and Pfizer; non-financial (travel) support from Eisai); and clinical trial unit support from IPD Australia; Anne Lynn S. Chang reports consulting and advisory roles at Regeneron Pharmaceuticals, Inc. and Merck; research funding from Regeneron Pharmaceuticals, Inc., Novartis, Genentech, and Merck; Karl D. Lewis reports grants and personal fees from Regeneron Pharmaceuticals, Inc. during the conduct of the study; Annette M. Lim reports uncompensated advisory board from Merck Sharp & Dohme and Bristol-Myers Squibb with travel and accommodation expenses; Leonel Hernandez-Aya reports consulting and advisory roles at Massive Bio; speakers' bureau roles at Sanofi and Regeneron Pharmaceuticals, Inc.; travel, accommodations, and expenses from Regeneron Pharmaceuticals, Inc., Sanofi, and Bristol-Myers Squibb; research funding from Bristol-Myers Squibb, Regeneron Pharmaceuticals, Inc., Immunocore, Merck Sharp & Dohme, Pfizer, Amgen, Celis Bioscience, Amgen, Merck, and Novartis; Brett G.M. Hughes reports consulting or advisory roles at Merck Sharp & Dohme, Bristol-Myers Squibb, AstraZeneca, Pfizer, Roche, Eisai, and Merck; institutional research funding from Amgen; Dirk Schadendorf reports institutional fees from Regeneron Pharmaceuticals, Inc.; advisory board honorarium fees from Amgen and Leo Pharma; speaker fee from Boehringer Ingelheim; advisory board, speaker honorarium and patients' fees from Roche, Novartis, Bristol-Myers Squibb, and Merck-EMD; advisory board and speaker honorarium fees from Inkyte and Pierre Fabre; advisory board honorarium and patients' fees from MSD; steering committee honorarium fees from ASC; advisory board and patients' fees from AstraZeneca, Pfizer, and Amgen; advisory board and patients' fees from Pfizer; Axel Hauschild reports institutional fees, honoraria, and consultancy fees from Amgen, Bristol-Myers Squibb, Merck Sharp & Dohme, Merck, Pierre Fabre, Proxcell, Roche, and Novartis; institutional grants and consultancy fees from Merck Serono, Pfizer, and Regeneron Pharmaceuticals, Inc.; consultancy fees from Oncoside; Michael R. Migden reports honoraria and travel expenses from Regeneron Pharmaceuticals, Inc., Sanofi, Novartis, Genentech, Eisai, and Sanofi; institutional research funding from Regeneron Pharmaceuticals, Inc., Novartis, Genentech, and Eisai; Elizabeth Stankevich, Jocelyn Booth, Siyu Li, Zhen Chen, Emmanuel Okoye, Israel Lowy, and Matthew G. Fury are employees and shareholders of Regeneron Pharmaceuticals, Inc.